Dr Asai on Final Results From a Phase 1/2 Trial of Tirabrutinib in R/R PCNSL
June 5th 2023Katsunori Asai, MD, PhD, Department of Neurosurgery, Osaka International Cancer Institute, Osaka, Japan, discusses the use of tirabrutinib in patients with relapsed/refractory primary central nervous system lymphoma according to a phase 1/2 study (JapicCTI-173646).